Literature DB >> 15767435

Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.

Emily J Platt1, James P Durnin, David Kabat.   

Abstract

Replication of human immunodeficiency virus type 1 (HIV-1) in diverse conditions limiting for viral entry into cells frequently leads to adaptive mutations in the V3 loop of the gp120 envelope glycoprotein. This has suggested that the V3 loop limits the efficiencies of HIV-1 infections, possibly by directly affecting gp120-coreceptor affinities. In contrast, V3 loop mutations that enable HIV-1(JR-CSF) to use the low-affinity mutant coreceptor CCR5(Y14N) are shown here to have negligible effects on the virus-coreceptor affinity but to dramatically accelerate the irreversible conformational conversion of the envelope gp41 subunits from a three-stranded coil into a six-helix bundle. This slow step is blocked irreversibly by the inhibitor T-20. To further evaluate the role of entry rates in controlling infection efficiencies and viral adaptations, we developed methods to quantitatively measure viral entry kinetics. The virions were adsorbed by spinoculation at 4 degrees C onto HeLa-CD4/CCR5 cell clones that either had limiting or saturating concentrations of CCR5. After warming to 37 degrees C, the completion of entry was monitored over time by the resistance of infections to the competitive CCR5 inhibitor TAK-779. Our results suggest that the efficiency of entry of cell-attached infectious HIV-1 is principally controlled by three kinetic processes. The first is a lag phase that is caused in part by the concentration-dependent reversible association of virus with CD4 and CCR5 to form an equilibrium assemblage of complexes. Second, this assembly step lowers but does not eliminate a large activation energy barrier for a rate-limiting, CCR5-dependent conformational change in gp41 that is sensitive to blockage by T-20. The rate of infection therefore depends on the fraction of infectious virions that are sufficiently saturated with CCR5 to undergo this conformational change and on the magnitude of the activation energy barrier. Although only a small fraction of fully assembled viral complexes overcome this barrier per hour, the ensuing steps of entry are rapidly completed within 5 to 10 min. Thus, this barrier limits the overall flow rate at which the attached virions enter cells, but it has no effect on the lag time that precedes this entry flow. Third, a relatively rapid and kinetically dominant process of viral inactivation, which may partly involve endocytosis, competes with infectious viral entry. Our results suggest that the V3 loop of gp120 has a major effect on the rate-limiting coreceptor-dependent conformational change in gp41 and that adaptive viral mutations, including V3 loop mutations, function kinetically by accelerating this inherently slow step in the entry pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767435      PMCID: PMC1061535          DOI: 10.1128/JVI.79.7.4347-4356.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1

Authors: 
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

2.  Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.

Authors:  U O'Doherty; W J Swiggard; M H Malim
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Fluorescence resonance energy transfer-based HIV-1 virion fusion assay.

Authors:  Marielle Cavrois; Jason Neidleman; Martin Bigos; Warner C Greene
Journal:  Methods Mol Biol       Date:  2004

Review 4.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

5.  Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.

Authors:  I Mondor; S Ugolini; Q J Sattentau
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

Review 7.  T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock.

Authors:  M D Hazenberg; D Hamann; H Schuitemaker; F Miedema
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

8.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more
  72 in total

1.  Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Authors:  Wei Wang; Christopher J De Feo; Min Zhuang; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

2.  Entry kinetics and cell-cell transmission of surface-bound retroviral vector particles.

Authors:  Lee S O'Neill; Amy M Skinner; Josha A Woodward; Peter Kurre
Journal:  J Gene Med       Date:  2010-05       Impact factor: 4.565

3.  Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor.

Authors:  Venice Du Pont; Christoph Wirblich; Jeong-Joong Yoon; Robert M Cox; Matthias J Schnell; Richard K Plemper
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

4.  Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane.

Authors:  Ruben M Markosyan; Fredric S Cohen; Grigory B Melikyan
Journal:  Mol Biol Cell       Date:  2005-09-29       Impact factor: 4.138

Review 5.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

6.  Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures.

Authors:  Hillel Haim; Israel Steiner; Amos Panet
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

7.  Stochastic entry of enveloped viruses: fusion versus endocytosis.

Authors:  Tom Chou
Journal:  Biophys J       Date:  2007-05-18       Impact factor: 4.033

8.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

9.  Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1.

Authors:  Alonso Heredia; Olga Latinovic; Robert C Gallo; Gregory Melikyan; Marv Reitz; Nhut Le; Robert R Redfield
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

10.  Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Authors:  Per Johan Klasse
Journal:  Virology       Date:  2007-09-07       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.